Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …

Background A single, high priming dose of tremelimumab (anti-cytotoxic T lymphocyte–
associated antigen 4) plus durvalumab (anti–programmed cell death ligand-1), an infusion …

Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer
patients and conferred durable clinical benefits, including cure in a subset of patients …

Abstract The phosphatidylinositol 3-kinase (PI3K)/Akt pathway plays a crucial role in various
cellular processes and is aberrantly activated in cancers, contributing to the occurrence and …

Immunotherapy has revolutionized cancer treatment, but efficacy remains limited in most
clinical settings. Cancer is a systemic disease that induces many functional and …

Immune checkpoint blockade, which blocks inhibitory signals of T cell activation, has shown
tremendous success in treating cancer, although success still remains limited to a fraction of …

The clinical use of molecular targeted therapy is rapidly evolving but has primarily focused
on genomic alterations. Transcriptomic analysis offers an opportunity to dissect the …

The cancer-immunity cycle provides a framework to understand the series of events that
generate anti-cancer immune responses. It emphasizes the iterative nature of the response …

Background Unresectable locally advanced or metastatic triple-negative (hormone-receptor–
negative and human epidermal growth factor receptor 2 [HER2]–negative) breast cancer is …